The Costs and Consequences of Methicillin-Resistant Staphylococcus aureus Infection Treatments in Canada
Andrew J Rosner, Debbie L Becker, Angelina H Wong and 2 more
Canadian Journal of Infectious Diseases and Medical Microbiology · 2004
doi:10.1155/2004/383461 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
BACKGROUND: A multinational randomized controlled trial has shown a trend toward early discharge of patients taking oral linezolid versus intravenous vancomycin (IV) in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Infection treatments resulting in shorter hospitalization durations are associated with cost savings from the hospital perspective.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.